VENTURA COUNTY
HEALTH CARE PLAN

PRIALT (ziconotide)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Prialt is a synthetic form of a peptide found in the marine snail *Conus magus* which binds to afferent nociceptive nerves of the dorsal horn in the spinal cord and blocks the calcium channels, resulting in inhibition of excitatory neurotransmitter release.

Authorization: intrathecal infusion for the management of severe chronic pain refractory to other modes of treatment

Dosing: initiate at no more than 2.4 mcg/day (0.1 mcg/hr) then titrate in similar increments 2-3 times per week to response (maximum 19.2 mcg/day; 0.8 mcg/hr). Average dose 6.9 mcg/day (0.29 mcg/hr). Faster titration rates may be necessary if there is an urgent need for analgesia.

PRECAUTIONS: cognitive impairment; dizziness/vertigo; nausea; increase in serum CK(MM); opiate withdrawal if opiate discontinued abruptly; infections (injection site, CSF);

DRUG INTERACTIONS: potentiation of other CNS depressants;

REFERENCES

Jain KK, "An Evaluation of Intrathecal Ziconotide for the Treatment of Chronic Pain," *Expert Opin Investig Drugs*, 2000, 9(10):2403-10.

Miljanich GP, "Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain," *Curr Med Chem*, 2004, 11(23):3029-40.

Staats PS, Yearwood T, Charapata SG, et al, "Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS: A

Randomized Controlled Trial," *JAMA*, 2004, 291(1):63-70.

Wermeling D, Drass M, Ellis D, et al, "Pharmacokinetics and Pharmacodynamics of Intrathecal Ziconotide in Chronic Pain Patients," *J Clin Pharmacol*,2003, 43(6):624-36.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review